The UK and US have forged a major trade agreement that will guarantee no levies on British pharmaceutical exports going into the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise expenditure on medicines through the public health system. This pledge guarantees that import taxes on these crucial goods will be held at zero for a timeframe of the next three years.
This agreement is in response to recent threats to hike tariffs on patented pharmaceutical imports, with potential rates floated up to double the cost.
"This agreement with the Britain reinforces the global environment for new treatments and establishes much-needed fairness to American-British medicine commerce," a release noted.
Trade Impact
Pharmaceuticals represent one of the the United Kingdom's biggest exports to the United States, which is by far the largest buyer for leading UK drugmakers.
Trade data indicate that in the 12 months to the end of the third quarter, the UK shipped medicines valued at billions to the US. This figure accounted for nearly one-fifth of total UK exports in that period.
"This agreement secures employment, increases investment and facilitates the UK to emerge as a worldwide center for medical research," a government official stated.
Key UK Commitments
The agreement includes several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to increase total public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates exceeded 20%.
Recent Tensions
The pact takes place against a protracted tension between the pharmaceutical industry and the British authorities over spending levels and approval rates.
The disagreement were exacerbated by assertions that US customers were charged several times more for the equivalent treatments than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been announced toward projects in the United States.
One official stated that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.
